Hims & Hers Stock Stays Hot Amid Peptides Buzz

Hims & Hers rose 4.5% to $25.52 after the FDA scheduled a July meeting on whether certain peptides can be added to compounds pharmacies may produce, a potential regulatory tailwind for the company’s GLP-1 business. The stock has nearly doubled from its Feb. 24 low of $13.74 and short interest remains elevated at 34.5% of float, while call activity surged to 131,000 contracts in the first hour. With 12 of 15 brokerages still at 'hold' and the stock clearing its descending 80-day moving average, sentiment is improving but remains speculative.

Analysis

HIMS is being re-rated less by fundamentals than by a three-way squeeze: regulatory optionality, crowded short positioning, and a volatility regime that makes upside convexity cheap relative to realized movement. The key second-order effect is that any incremental FDA flexibility on compounding does not need to unlock a full addressable market to matter; it only has to extend the duration of the GLP-1 narrative and reduce the probability of a near-term growth air-pocket. That is enough to force systematic short covering and keep call demand elevated even if the underlying business thesis remains debated.

The market is likely underestimating how reflexive this setup can become over the next 2-6 weeks. A stock with this much short interest and a high implied-vs-realized mismatch can overshoot materially on limited incremental news, especially when dealer hedging flows are likely to chase the move higher as weekly strikes get pinched. The more important question is not whether the FDA outcome is ultimately favorable, but whether the event calendar creates a multi-week window where positioning, not fundamentals, dominates price discovery.

The contrarian risk is that this is a classic tape-driven squeeze into an event that may not produce the clean bullish binary traders want. If the FDA language is narrower than expected, or if the company’s GLP-1 monetization remains constrained by supply, margin, or legal uncertainty, the stock could give back a large portion of the recent move quickly. Over a 1-3 month horizon, the stock’s biggest vulnerability is that speculative call buying can leave late entrants paying for upside that has already been front-run by shorts and momentum funds.

Consensus is focused on the regulatory headline; what’s missing is that the real winner may be option sellers only if they can withstand the path dependency. The stock’s volatility profile suggests premium buyers have had a favorable payoff distribution, but that cuts both ways: when a heavily shorted name becomes a call magnet, the move can extend further than fundamentals justify. This is less a fundamental long than a squeeze-conditioned momentum trade with a hard catalyst window.

Key Decisions for Investors

• Tactically long HIMS for the next 2-6 weeks into the FDA meeting; use a tight stop below the recent breakout area because the trade is driven by positioning, not valuation. Risk/reward is favorable as long as short-covering persists, but expected edge collapses if event-driven momentum stalls.
• For convexity, buy near-dated HIMS calls only if you can source them with limited theta bleed; favor call spreads over outright calls to control premium in case the regulatory outcome is muted. Best suited for the 1-4 week window around the FDA calendar.
• If already long HIMS equity, hedge with a partial short-dated call overwrite into strength to monetize elevated implied volatility. This is attractive because the stock can remain range-bound after the squeeze while IV stays rich.
• Watch for a potential pair trade: long HIMS / short a basket of high-multiple telehealth or consumer-health peers if HIMS continues to separate on sentiment and flow. The edge is in positioning divergence, not sector fundamentals.
• Reduce exposure or take profits aggressively if the stock fails to hold gains after the FDA event, since post-event air pockets can be severe when call activity is crowded. A failed catalyst would likely trigger de-grossing over 1-2 sessions.